reproducTive endocrinology Late-onset hypogonadism: evidence for diagnostic criteria
Stephanie T. Page various symptoms are typical of severe testosterone deficiency in young men; in aging men, however, these symptoms are nonspecific and overlap with symptoms of other prevalent disorders. a new study offers evidence-based criteria for the identification of late-onset hypogonadism in the general population on the basis of an association between symptoms and a low testosterone level.
serum testosterone concentrations fall as men age, such that almost 50% of men aged >80 years could be defined as hypogonadal on the basis of biochemical evidence alone. 1 Given the nonspecific nature of many of the symptoms associated with testosterone defi ciency, uncertainty exists as to whom to consider as a candidate for testo sterone replacement. the work of wu et al. 2 provides some novel information regarding the epi demiology of the syndrome of late-onset hypogonadism.
in a recent issue of the New England Journal of Medicine, the investigators report the results of the european male aging study, a very large cross-sectional survey of 3,369 men, aged 40-79 years, from eight euro pean centers. employing a unique approach facilitated by their relatively large sample size, the investigators first randomly divided the cohort into a training group and a validation group. any associations were initially examined in the training group and then independently evaluated in the validation group, thus enabling corroboration of their definitions and conclusions.
From questionnaire data, the researchers identified nine symptoms that were associated with low serum testosterone concentrations: three sexual symptoms (poor morning erection, erectile dys function or low sexual desire), three physical symptoms (dif ficulties in performing vigo rous activity, walking >1 km or bending, kneeling or stooping) and three psychological symptoms (sadness, energy loss or fatigue). using morning testosterone levels from the training group, the investi gators defined thresholds of serum testosterone for each symptom below which the prevalence of these conditions increased signi ficantly. interestingly, the prevalence of each symptom increased at different threshold levels of testo sterone; for example, low sexual desire (determined by a decreased frequency of sexual thoughts) was more frequently associated with testo sterone concentrations <8.5 nmol/l, whereas diminished vigor was associated with testosterone levels <13.0 nmol/l.
in an effort to synthesize these data to define a syndrome of late-onset hypo gonadism rather than a checklist of various symptoms, wu et al. used rigorous and complex statistical analyses to determine whether any cluster of symptoms were, together, strongly associated with testo sterone levels below a threshold concentration. with this approach, only the three sexual symptoms were significantly clustered with one another and with a low total testosterone level. importantly, these associa tions were confirmed in the validation group. wu and colleagues conclude that the presence of these three sexual symptoms and a morning total testosterone level <11 nmol/l can be considered an evidencebased, minimum criteria for the diagnosis of late-onset male hypogonadism. one of the clear strengths of this study is the population-based study design, which included a sampling of men across ages, countries and ethnicities. How ever, the respondent population was relatively healthy compared with men one might encoun ter in clinical practice. For example, the average number of comorbidities among us veterans seeking ambulatory care was >5, compared news & views with roughly 1 in the cohort by wu and co-workers. 3 this discordance is of particular importance when analyzing syndrome prevalence. using the criteria of wu et al., the overall prevalence of late-onset hypogonadism in the study cohort was only 3% and 5% in men aged 60-69 years and 70-79 years, respectively, and thus much lower than the prevalence reported elsewhere using similar definitions. 4 the investigators' supplementary data is consistent with previous studies that report an increased incidence of lateonset hypo gonadism with increasing bmi and comorbidities; however, an analysis of the data that combines these factors and syndrome prevalence is lacking. moreover, men with primary testicular failure or pituitary disease were specifically excluded from the analysis. such patients might present to a clinic with very low testo sterone levels (<6.9 nmol/l) and may not have sexual complaints, but should nonetheless be considered for therapy. Providers should, therefore, not extrapolate the reported preva lence rates to patients who seek medical care and present with signs, symptoms or clear laboratory abnormalities that suggest hypogonadism.
the data presented by wu and colleagues is indicative of the nonspecificity of many symptoms associated with hypogonadism. sexual symptoms were present in >25% of middle-aged and older men with serum testosterone levels in the normal range for healthy, young men. the overlap of symptoms of hypogonadism with other aging-associated syndromes and diseases highlights the importance of using a combina tion of biochemical and symptomatic data for the diagnosis and potential treatment of male late-onset hypogonadism. 5 However, the absolute values of serum testosterone that define late-onset hypogonadism, as suggested by the researchers, are difficult to translate into clinical practice. the study by wu et al. utilized a central lab with state-of-the-art measurements for testo sterone (gas chromatography-mass spectro metry). in practice, clinicians use clinical laboratories that employ a variety of analytical methods that are notoriously variable in the quantifica tion of serum levels of sex steroids. 6 Consistent with current clinical guidelines, clinicians should use the lower limit of the normal range of serum testosterone levels for healthy young men (as defined by their reference laboratory) when con sidering the diagnosis of late-onset hypogonadism. 5 notably, the level of serum testosterone that defines late-onset hypogonadism in the study by wu and colleagues is near the lower limit of the normal range for many reference laboratories. 5 Finally, wu et al. are very careful to point out that their findings should not be used to define which patients might benefit from testosterone therapy. the investigators did not observe a linear relationship between symptoms and testosterone levels beyond the observed threshold levels. this result is consistent with an intervention study that did not show any improvement in aspects of sexual function, cognition or mood with increasing doses of exogenous testosterone after serum levels in the mid-normal range had been achieved. 7 moreover, the low preva lence of hypogonadism in the study by wu and co-workers and the high prevalence of symptoms associated with hypogonadism in men with normal testosterone levels is a reminder of the potential for 'over treatment' of age-associated declines in testosterone. on the one hand, epidemiologic studies have found low testo sterone levels to be associated with early mortality, and a metaanalysis of testo sterone intervention trials suggests that the risk of adverse events with replacement therapy is low. 8 However, in a report by basaria et al., 9 the improvement of physical function observed in elderly men with mo bility impairment and multiple comorbid conditions treated with exogenous testosterone therapy came at the expense of an increased risk of cardio vascular events. 9 although these findings should not be extrapolated to the general population, as the cohort of basaria et al. 9 included only a very select population of men treated with higher doses of testosterone than have been used in other studies, they serve as a reminder that strong evidence regarding the long-term risks and benefits of testosterone re placement is lacking.
Patients are clearly interested in androgenbased therapies, as evidenced by the marked increase in testosterone prescriptions over the last decade. 10 the work of wu et al. has demonstrated which symptoms of aging are most closely associated with reduced concentrations of circulating testosterone, and their results confirm a current guideline 5 that recom mends a combination of low testo sterone levels and presence of symptoms, such as decreased libido and spontaneous erections, hot flushes, or mild anemia, as the best definition of late-onset hypogonadism. ultimately, this study has important implications for the design of much needed, larger, randomized, placebo-controlled trials of testosterone therapy in older men that will provide a true understanding of its risks and benefits. 
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